DEVELOPMENT, IN VITRO AND IN VIVO EVALUATION OF RISEDRONATE SODIUM FLOATING MICROBALLOONS

Dr. Shayeda*, Dr. Munija Pancheddula, Malagam Mithila and Chittipolu Ajay Kumar

The present investigation is concerned with the formulation and evaluation of Risedronate Sodium floating microballoons to extend gastric residence time (GRT) and to prolong the release of the drug. In the present work by solvent evaporation process, floating microballoons of Risedronate sodium were formulated. The prepared microballoons were subjected for both In vitro and In vivo evaluation. Out of all formulations the formulation (RSF10) with Eudragit RS 100, Eudragit S 100 in 1:1 ratio has noticed maximum amount of drug release hence, considered as the optimized formulation. The in vitro release kinetics demonstrated that the optimised formulation releases the drug in a zero-order manner based on the regression values of kinetic models. For in vivo assessment, the optimised formulation was subjected to in vivo radiographic analysis and in vivo pharmacokinetic analysis. The optimized formulation remained buoyant in the stomach for up to 5.5 h and the oral bioavailability of the improved formulation was substantially higher than that of the formulations put on the market. The improved bioavailability may be due to the longer-lasting floating function of the dosage form in the stomach.